Lynparza On Track For Broad Frontline Use In Prostate Cancer
Leading PARP Inhibitor’s Uses Keep Expanding
Executive Summary
AstraZeneca and Merck & Co’s latest results put them far ahead of competitors in prostate cancer in reaching patient regardless of their mutational status.
You may also be interested in...
AstraZeneca/Merck Reinforce Lynparza’s Prostate Cancer Position With First-Line Data
The companies published data showing the drug was effective in patients with both homologous recombinant repair mutated and non-mutated disease.
SIFI Among EU Fast-Track Hopefuls With ‘World’s First’ Drug For Parasitic Eye Infection
SIFI is set to learn whether the European Medicines Agency will agree that its planned EU marketing application for Akantior merits an accelerated assessment, as is Janssen for its combination treatment for prostate cancer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Lynparza poised for expansion in prostate cancer; zuranolone faces challenges in depression; Novartis transfers products and cuts jobs in India; US call to build Alzheimer’s infrastructure; and Indian legal row over COVID spray product.